Microsatellite Instability (MSI)
Microsatellite Instability (MSI) is a molecular phenomenon characterized by mutations or instability in short repetitive DNA sequences called microsatellites. These microsatellites are prone to errors during DNA replication, and MSI occurs due to defects in the DNA mismatch repair (MMR) system, which normally corrects such errors. MSI is a hallmark of certain cancers and has important diagnostic, prognostic, and therapeutic implications.
Key Features of Microsatellite Instability (MSI)
Definition
- Microsatellites: Short, repetitive DNA sequences consisting of mono-, di-, tri-, or tetranucleotide repeats, scattered throughout the genome.
- Microsatellite Instability (MSI): A condition where these microsatellite regions exhibit mutations or instability due to defective MMR, leading to insertion or deletion errors during DNA replication.
Mechanism of MSI
Normal DNA Mismatch Repair (MMR) System:
- The MMR system is responsible for correcting replication errors, such as base mismatches and insertion-deletion loops.
- Key MMR genes include:
- MLH1 (MutL homolog 1)
- MSH2 (MutS homolog 2)
- MSH6 (MutS homolog 6)
- PMS2 (Post-Meiotic Segregation 2)
Defective MMR:
- Loss of function in one or more MMR genes prevents the correction of replication errors.
- This leads to instability in microsatellite regions, resulting in mutations that can affect oncogenes and tumor suppressor genes, contributing to cancer development.
Causes of MSI
Hereditary Causes:
- Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer, HNPCC):
- Caused by germline mutations in MMR genes (e.g., MLH1, MSH2, MSH6, PMS2).
- Autosomal dominant inheritance.
- Associated with colorectal, endometrial, ovarian, and gastric cancers.
Sporadic Causes:
- Epigenetic Silencing:
- Hypermethylation of the MLH1 promoter, leading to loss of MLH1 expression.
- Common in sporadic colorectal and gastric cancers.
- Somatic Mutations:
- Acquired mutations in MMR genes.
Clinical Features of MSI
Cancers Associated with MSI:
- Colorectal Cancer:
- MSI is present in ~15% of sporadic colorectal cancers and >90% of Lynch syndrome-associated colorectal cancers.
- Typically occurs in the proximal colon.
- Gastric Cancer:
- MSI is found in ~10–50% of sporadic gastric cancers.
- Endometrial Cancer:
- MSI is identified in ~30% of endometrial cancers.
- Other Cancers:
- Ovarian, pancreatic, hepatobiliary, and small intestinal cancers.
Prognostic Features:
- MSI-High (MSI-H) tumors:
- Associated with better prognosis in colorectal cancer (stage-adjusted survival advantage).
- Reduced likelihood of lymph node metastasis.
- Increased tumor mutational burden (TMB), leading to enhanced immunogenicity.
Diagnostic Approach for MSI
Indications for MSI Testing:
- Suspected Lynch Syndrome:
- Early-onset colorectal or endometrial cancer.
- Family history of Lynch-associated cancers.
- Sporadic Colorectal or Gastric Cancer:
- Routine testing in cancer management.
Methods of MSI Detection:
- Immunohistochemistry (IHC):
- Detects expression of MMR proteins (MLH1, MSH2, MSH6, PMS2).
- Loss of protein expression indicates defective MMR.
- Polymerase Chain Reaction (PCR):
- Identifies instability in predefined microsatellite markers (e.g., BAT25, BAT26).
- Tumors are classified as:
- MSI-High (MSI-H): Instability in ≥30% of markers.
- MSI-Low (MSI-L): Instability in <30% of markers.
- Microsatellite Stable (MSS): No instability.
- Next-Generation Sequencing (NGS):
- Detects MSI and tumor mutational burden (TMB).
- MLH1 Promoter Methylation Testing:
- Used to distinguish epigenetic silencing of MLH1 in sporadic cancers from Lynch syndrome.
Therapeutic Implications of MSI
Immune Checkpoint Inhibitors:
- MSI-H tumors have high TMB, resulting in increased neoantigen expression and enhanced tumor immunogenicity.
- Immune checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4 are highly effective in MSI-H tumors.
- Example: Pembrolizumab (anti-PD-1 therapy) is approved for MSI-H metastatic cancers.
Chemotherapy:
- MSI-H colorectal cancers show poor response to 5-fluorouracil (5-FU)-based chemotherapy.
- Alternative chemotherapy regimens may be required.
Targeted Therapy:
- Research is ongoing to develop MSI-specific molecular therapies.
Prognosis of MSI-H Tumors
| Tumor Type | MSI-H Tumors | MSS Tumors |
|---------------------------|---------------------------------------------------|-------------------------------------------------|
| Prognosis | Better overall prognosis due to immune activation | Worse prognosis in many cancers |
| Response to Immunotherapy | Excellent response to immune checkpoint inhibitors | Poor response |
| Chemotherapy Sensitivity | Reduced sensitivity to 5-FU-based chemotherapy | Standard chemotherapy response |
Summary Table
| Feature | Microsatellite Instability (MSI) |
|----------------------------|-------------------------------------------------|
| Definition | Instability in short tandem DNA repeats due to defective MMR |
| Causes | Lynch syndrome (hereditary), MLH1 promoter methylation (sporadic) |
| Associated Cancers | Colorectal, gastric, endometrial, ovarian |
| Diagnostic Methods | IHC, PCR, NGS, MLH1 promoter methylation testing |
| Therapeutic Implications | Immune checkpoint inhibitors (e.g., pembrolizumab) |
| Prognosis | Better prognosis in MSI-H tumors |
Clinical Pearls
- MSI Testing:
- Essential in colorectal and endometrial cancers to identify Lynch syndrome and guide therapy decisions.
- Immunotherapy:
- MSI-H tumors respond exceptionally well to immune checkpoint inhibitors, making MSI status crucial for treatment planning.
- Prognostic Value:
- MSI-H tumors generally have a better prognosis due to their immunogenicity.
Takeaway Points
- Microsatellite instability (MSI) results from defective DNA mismatch repair and is a hallmark of Lynch syndrome and sporadic cancers.
- MSI testing is critical for diagnosis, prognosis, and therapeutic decision-making, particularly in colorectal and gastric cancers.
- MSI-H tumors benefit significantly from immune checkpoint inhibitors, revolutionizing treatment in advanced cancers.
